A Study Into the Pharmacodynamic Biomarker Effects of Olaparib (a PARP Inhibitor) ± Degarelix (a GnRH Antagonist) Given Prior to Radical Prostatectomy
Phase of Trial: Phase I
Latest Information Update: 11 Jan 2017
At a glance
- Drugs Olaparib (Primary) ; Degarelix
- Indications Prostate cancer
- Focus Pharmacodynamics
- Sponsors AstraZeneca
- 07 Jun 2017 Biomarkers information updated
- 06 Jan 2017 Planned End Date changed from 1 May 2017 to 1 Jul 2018.
- 06 Jan 2017 Planned primary completion date changed from 1 May 2016 to 1 Jun 2018.